Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:DSGN NASDAQ:RNA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.63+1.0%$4.86$1.46▼$5.88$785.61M0.761.93 million shs195,471 shsDSGNDesign Therapeutics$11.94+0.6%$12.60$3.76▼$17.25$746.40M1.58596,059 shs78,154 shsRNAAvidity Biosciences$12.14+3.2%$12.75$11.40▼$16.77$207.67M0.93445,629 shs72,598 shsZVRAZevra Therapeutics$12.36+2.8%$12.34$7.16▼$15.03$731.31M0.851.32 million shs326,446 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.94%+1.27%+23.78%+33.57%+245.96%DSGNDesign Therapeutics-5.57%-14.30%-4.58%-10.68%+198.24%RNAAvidity Biosciences-3.21%-3.76%-7.11%-13.08%-65.17%ZVRAZevra Therapeutics-5.79%-8.73%-6.74%+15.78%-0.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.63+1.0%$4.86$1.46▼$5.88$785.61M0.761.93 million shs195,471 shsDSGNDesign Therapeutics$11.94+0.6%$12.60$3.76▼$17.25$746.40M1.58596,059 shs78,154 shsRNAAvidity Biosciences$12.14+3.2%$12.75$11.40▼$16.77$207.67M0.93445,629 shs72,598 shsZVRAZevra Therapeutics$12.36+2.8%$12.34$7.16▼$15.03$731.31M0.851.32 million shs326,446 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.94%+1.27%+23.78%+33.57%+245.96%DSGNDesign Therapeutics-5.57%-14.30%-4.58%-10.68%+198.24%RNAAvidity Biosciences-3.21%-3.76%-7.11%-13.08%-65.17%ZVRAZevra Therapeutics-5.79%-8.73%-6.74%+15.78%-0.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50106.46% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5039.01% UpsideRNAAvidity Biosciences 2.28Hold$67.60474.83% UpsideZVRAZevra Therapeutics 2.82Moderate Buy$29.29143.44% UpsideCurrent Analyst Ratings BreakdownLatest RNA, ACRS, DSGN, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026ZVRAZevra Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/19/2026RNAAvidity Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/18/2026RNAAvidity Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.006/10/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $29.006/10/2026ZVRAZevra Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $35.006/9/2026ZVRAZevra Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $29.006/9/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/9/2026ZVRAZevra Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M99.35N/AN/A$0.85 per share6.55DSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/ARNAAvidity Biosciences$36.68M5.48N/AN/A$10.88 per share1.08ZVRAZevra Therapeutics$106.47M6.68$0.89 per share13.50$2.75 per share4.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)RNAAvidity Biosciences-$322.30M-$0.97N/AN/AN/A-3,650.39%-44.92%-39.57%8/13/2026 (Estimated)ZVRAZevra Therapeutics$83.23M$1.996.0512.66N/A101.58%51.49%28.86%8/11/2026 (Estimated)Latest RNA, ACRS, DSGN, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026RNAAvidity Biosciences-$1.1833N/AN/AN/A$0.67 millionN/A8/11/2026Q2 2026ZVRAZevra Therapeutics$0.08N/AN/AN/A$33.88 millionN/A8/6/2026Q2 2026ACRSAclaris Therapeutics-$0.16N/AN/AN/A$1.38 millionN/A8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03DSGNDesign TherapeuticsN/A22.2822.28RNAAvidity BiosciencesN/A9.2011.57ZVRAZevra TherapeuticsN/A4.894.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%DSGNDesign Therapeutics56.64%RNAAvidity BiosciencesN/AZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%DSGNDesign Therapeutics17.10%RNAAvidity Biosciences3.83%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableRNA, ACRS, DSGN, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street ZenJuly 12, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Down 4.8% - What's Next?July 9, 2026 | marketbeat.comAIGH Capital Management LLC Acquires New Position in Zevra Therapeutics, Inc. $ZVRAJuly 9, 2026 | marketbeat.comZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)June 23, 2026 | globenewswire.comZevra Therapeutics: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | finanznachrichten.deZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | markets.businessinsider.comZevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | globenewswire.comIs Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?June 9, 2026 | finance.yahoo.comZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?June 9, 2026 | finance.yahoo.comZevra Therapeutics extends MIPLYFFA exclusivity to 2041June 8, 2026 | finance.yahoo.comZVRA stock ‘way undervalued’? Analyst sees 117% upside after patent extends exclusivity till 2041 for sole approved drugJune 8, 2026 | msn.comZevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFAJune 8, 2026 | globenewswire.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comZevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)May 11, 2026 | theglobeandmail.comZevra Therapeutics Earnings Call Highlights Growth PivotMay 10, 2026 | tipranks.comZevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 9, 2026 | finance.yahoo.comZevra Therapeutics: Q1 Earnings SnapshotMay 7, 2026 | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWashington’s Quantum Push Puts IBM and IonQ on the ThroneBy Jeffrey Neal Johnson | June 25, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026General Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsBy Thomas Hughes | July 2, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026Short Squeeze Alert—Moderna Stock Surges on New StrategyBy Chris Markoch | July 1, 2026RNA, ACRS, DSGN, and ZVRA Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.62 +0.06 (+0.99%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Design Therapeutics NASDAQ:DSGN$11.94 +0.07 (+0.59%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Avidity Biosciences NASDAQ:RNA$12.14 +0.38 (+3.23%) As of 11:51 AM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Zevra Therapeutics NASDAQ:ZVRA$12.36 +0.33 (+2.75%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
